Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Nagashunmugam T, Lubinski J, Wang L, Goldstein LT, Weeks BS, Sundaresan P, Kang EH, Dubin G, Friedman HM.

J Virol. 1998 Jul;72(7):5351-9.

3.

The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.

Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM.

J Virol. 2011 Apr;85(7):3239-49. doi: 10.1128/JVI.02509-10. Epub 2011 Jan 12.

4.
5.

Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.

Hook LM, Huang J, Jiang M, Hodinka R, Friedman HM.

J Virol. 2008 Jul;82(14):6935-41. doi: 10.1128/JVI.02599-07. Epub 2008 May 14.

6.

Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Chu CF, Meador MG, Young CG, Strasser JE, Bourne N, Milligan GN.

J Reprod Immunol. 2008 Jun;78(1):58-67. Epub 2007 Oct 24.

7.

Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.

Lubinski JM, Jiang M, Hook L, Chang Y, Sarver C, Mastellos D, Lambris JD, Cohen GH, Eisenberg RJ, Friedman HM.

J Virol. 2002 Sep;76(18):9232-41.

8.

Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Awasthi S, Lubinski JM, Friedman HM.

Vaccine. 2009 Nov 16;27(49):6845-53. doi: 10.1016/j.vaccine.2009.09.017. Epub 2009 Sep 15.

9.

Viral interference with antibody and complement.

Lubinski J, Nagashunmugam T, Friedman HM.

Semin Cell Dev Biol. 1998 Jun;9(3):329-37. Review.

PMID:
9665870
10.

Immune evasion by herpes simplex virus type 1, strategies for virus survival.

Friedman HM.

Trans Am Clin Climatol Assoc. 2003;114:103-12.

11.

Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells.

Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC.

J Virol. 1994 Feb;68(2):834-45.

13.

Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease.

Saldanha CE, Lubinski J, Martin C, Nagashunmugam T, Wang L, van Der Keyl H, Tal-Singer R, Friedman HM.

J Virol. 2000 Aug;74(15):6712-9.

17.

The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.

Peng T, Ponce-de-Leon M, Jiang H, Dubin G, Lubinski JM, Eisenberg RJ, Cohen GH.

J Virol. 1998 Jan;72(1):65-72.

18.

A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors.

Corrales-Aguilar E, Trilling M, Reinhard H, Mercé-Maldonado E, Widera M, Schaal H, Zimmermann A, Mandelboim O, Hengel H.

J Immunol Methods. 2013 Jan 31;387(1-2):21-35. doi: 10.1016/j.jim.2012.09.006. Epub 2012 Sep 27.

PMID:
23023090
19.

The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface.

Ndjamen B, Farley AH, Lee T, Fraser SE, Bjorkman PJ.

PLoS Pathog. 2014 Mar 6;10(3):e1003961. doi: 10.1371/journal.ppat.1003961. eCollection 2014 Mar.

20.

Mapping regions of herpes simplex virus type 1 glycoprotein I required for formation of the viral Fc receptor for monomeric IgG.

Basu S, Dubin G, Nagashunmugam T, Basu M, Goldstein LT, Wang L, Weeks B, Friedman HM.

J Immunol. 1997 Jan 1;158(1):209-15.

PMID:
8977192

Supplemental Content

Support Center